MedTrace Logo

Mid-life Women: Preventing Unintended Pregnancy and STIs

NCT02330133 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 333

Last updated 2015-01-01

No results posted yet for this study

Summary

Mid-life women, aged 35-50, are currently an underserved population in the areas of unintended pregnancy and STI prevention interventions. Common perception is that women in this age range are no longer sexually active, or are past the menopause transition, but in reality, sexual activity remains stable through mid-life and into the post-menopausal years. Additionally, physiological and relationship status changes (e.g. divorce or death of a partner) put these women at increased risk for both unintended pregnancy and STI's. This project developed and evaluated a theoretically-based multimedia intervention designed to assist mid-life women in protecting themselves from sexually transmitted infections and unintended pregnancy.

Conditions

  • Reproductive Health

Interventions

BEHAVIORAL

Women's Reproductive Health

Targeted text and video information on website for women aged 25-55 to avoid unplanned pregnancy and sexually transmitted infections

BEHAVIORAL

Online sexual health content

Online general text-based information about reproductive health issues and strategies for preventing sexually transmitted infections

Sponsors & Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    collaborator NIH

  • Oregon Center for Applied Science, Inc.

    lead INDUSTRY

Principal Investigators

  • Lynne H Grilley Swartz, MPH, CHES · Oregon Center for Applied Science

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02330133 on ClinicalTrials.gov